Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pb-212-RMX-VH
- Development stage
- Preclinical
- Lead developer
- Radiomedix
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
Pb-212-RMX-VH (also known as 212Pb-RMX-VH or 212Pb-RMX-VH-PKM in its second-generation formulation) is an investigational targeted alpha therapy (TAT) radiopharmaceutical being co-developed by RadioMedix and Vect-Horus. It consists of a peptide vector (RMX-VH) designed to target the Low-Density Lipoprotein Receptor (LDLR), which is highly overexpressed in various solid tumors, conjugated to the alpha-emitting radioisotope lead-212 (Pb-212) via a DOTAM chelator. By binding to LDLR, the radioconjugate is internalized into cancer cells, where the decay of Pb-212 delivers high-energy, short-range alpha radiation that induces lethal DNA double-strand breaks. Pb-212-RMX-VH is currently in preclinical development (Pharma/Tox stage) for the treatment of glioblastoma (GBM) and pancreatic ductal adenocarcinoma (PDAC), supported by companion diagnostic imaging agents such as 203Pb-RMX-VH-PIB.
- Other names
- 212Pb-RMX-VH-PKM212Pb-labeled LDLR-targeting peptidelead-212 RMX-VHlead212 RMX-VHlead 212 RMX-VH
02
Targets
LDLR (Low-density lipoprotein receptor)DNA
Beyond the preview
Go deeper on Pb-212-RMX-VH.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pb-212-RMX-VH.